Advertisement

Heart Failure Reviews

, Volume 15, Issue 5, pp 467–477 | Cite as

Resveratrol and red wine, healthy heart and longevity

  • Dipak K. DasEmail author
  • Subhendu Mukherjee
  • Diptarka Ray
Article

Abstract

Resveratrol, a polyphenol phytoalexin, present in red wine and grapes possesses diverse biochemical and physiological properties, including estrogenic, antiplatelet, and anti-inflammatory properties as well as a wide range of health benefits ranging from chemoprevention to cardioprotection. Recently, several studies described resveratrol as an anti-aging compound. This review focuses on the anti-aging aspects of resveratrol, the possible mechanisms of action, and emerging controversy on its life-prolonging ability. It appears that resveratrol can induce the expression of several longevity genes including Sirt1, Sirt3, Sirt4, FoxO1, Foxo3a and PBEF and prevent aging-related decline in cardiovascular function including cholesterol level and inflammatory response, but it is unable to affect actual survival or life span of mice.

Keywords

Resveratrol Red wine White wine Cardioprotection Longevity genes Anti-aging SIRT FoxO PBEF 

Abbreviations

SIRT

Sirtuins.

FoxO

Forkhead transcription factor.

PBEF

Pre B cell colony enhancing factor.

LDL

Low-density lipoprotein.

BMR

Basal metabolic rate.

CR

Calorie restriction.

IGF1

Insulin-dependent growth factor 1

ROS

Reactive oxygen species

NOS

Nitric oxide synthase

VEGF

Vascular endothelial growth factor

GLUT

Glucose transporter type 4

PUFA

Polyunsaturated fatty acids

HO-1

Heme oxygenase-1

PKC

Protein kinase C

PI3 kinase

Phosphatidylinositol-3-kinase

LPS

Lipopolysaccharide

PGE2

Prostaglandin E2

TNFα

Tumor necrosis factor α

Notes

Acknowledgements

This study was supported by NH HL 34360, HL22559 and HL33889.

References

  1. 1.
    Bertelli AA, Das DK (2009) Grapes, wines, resveratrol and heart health. J Cardiovasc Pharmacol 54:468–476Google Scholar
  2. 2.
    Kopp P (1998) Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the ‘French paradox’? Eur J Endocrinol 38(6):619–620Google Scholar
  3. 3.
    Wang Z, Zou J, Cao K, Hsieh TC, Huang Y, Wu JM (2005) Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med. 16(4):533–540PubMedGoogle Scholar
  4. 4.
    Das DK, Sato M, Ray PS, Maulik G, Engelman RM, Bertelli AA, Bertelli A (1999) Drugs exp. Clin Res 25(2–3):115–120Google Scholar
  5. 5.
    Castello L, Tessitore L (2005) Resveratrol inhibits cell cycle progression in U937 cells. Oncol Rep 13(1):133–137PubMedGoogle Scholar
  6. 6.
    Zhuang H, Kim YS, Koehler RC, Doré S (2003) Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann N Y Acad Sci 993:276–286 discussion 287–288PubMedGoogle Scholar
  7. 7.
    Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA (2003) Small molecule activators of sirutins extend Saccharomyces cerevisiae lifespan. Nature 425(6954):191–196PubMedGoogle Scholar
  8. 8.
    Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5(6):493–506PubMedGoogle Scholar
  9. 9.
    Mukherjee S, Lekli I, Gurusamy N, Bertelli AA, Das DK (2009) Expression of the longevity proteins by both red and white wines and their chemoprotective components, resveratrol, tyrosol, and hydroxytyrosol. Free Radic Biol Med 46(5):573–578PubMedGoogle Scholar
  10. 10.
    Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliot PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8(2):157–168PubMedGoogle Scholar
  11. 11.
    Mittlemark BM, Rautaharju PM (1993) Prevalence of cardiovascular diseases among older adults. The Cardiovascular Health Study. Am J Epidemiol 137:311–334Google Scholar
  12. 12.
    Rezzi S, Martin FP, Shanmuganayagam D, Colman RJ, Nicholson JK, Weindruch R (2009) Metabolic shifts due to long-term caloric restriction revealed in nonhuman primates. Exp Gerontol 44(5):356–362PubMedGoogle Scholar
  13. 13.
    Walford RL (1988) The retardation of aging and disease by dietary restriction. Richard Weindruch, ISBN 0-398-05496-7Google Scholar
  14. 14.
    Mattson MP (2005) Energy intake, meal frequency, and health: a neurobiological perspective. Ann Rev Nutr 25:237–260Google Scholar
  15. 15.
    Richard JL (1987) Coronary risk factors. The French paradox. Arch Mal Coeur Vaiss 80 Spec No:17–21Google Scholar
  16. 16.
    Hattori R, Otani H, Maulik N, Das DK (2002) Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol 282:H1988–H1995PubMedGoogle Scholar
  17. 17.
    Cadenas S, Barja G (1999) Resveratrol, melatonin, vitamin E, and PBN protect against renal oxidative DNA damage induced by the kidney carcinogen KBrO3. Free Radic Biol Med 26:1531–1537PubMedGoogle Scholar
  18. 18.
    Imamura G, Bertelli AA, Bertelli A, Otani H, Maulik N, Das DK (2002) Pharmacological preconditioning with resveratrol: an insight with iNOS knockout mice. Am J Physiol Heart Circ Physiol 282:H1996–H2003PubMedGoogle Scholar
  19. 19.
    Das S, Alagappan VK, Bagchi D, Sharma HS, Maulik N, Das DK (2005) Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol 42:281–289PubMedGoogle Scholar
  20. 20.
    Fukuda S, Kaga S, Zhan L, Bagchi D, Das DK, Bertelli A, Maulik N (2006) Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem Biophys 44:43–49PubMedGoogle Scholar
  21. 21.
    Das S, Cordis GA, Maulik N, Das DK (2005) Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am J Physiol Heart Circ Physiol 288:H328–H335PubMedGoogle Scholar
  22. 22.
    Das S, Falchi M, Bertelli A, Maulik N, Das DK (2006) Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol. Arzneimittelforschung 56:700–706PubMedGoogle Scholar
  23. 23.
    Das S, Fraga CG, Das DK (2006) Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI-3-kinase signaling, but does not involve NFkappaB. Free Radic Res 40:1066–1075PubMedGoogle Scholar
  24. 24.
    Das S, Tosaki A, Bagchi D, Maulik N, Das DK (2006) Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J Pharmacol Exp Ther 317:980–988PubMedGoogle Scholar
  25. 25.
    Dekkers DH, Bezstarosti K, Gurusamy N, Luijk K, Verhoeven AJ, Rijkers EJ, Demmers JA, Lamers JM, Maulik N, Das DK (2008) Identification by a differential proteomic approach of the induced stress and redox proteins by resveratrol in the normal and diabetic rat heart. J Cell Mol Med 12:1677–1689PubMedGoogle Scholar
  26. 26.
    Lekli I, Szabo G, Juhasz B, Das S, Das M, Varga E, Szendrei L, Gesztelyi R, Varadi J, Bak I, Das DK, Tosaki A (2008) Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol 294:H859–H866PubMedGoogle Scholar
  27. 27.
    Yen GC, Duh PD, Lin CW (2003) Effects of resveratrol and 4-hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res 37:509–514PubMedGoogle Scholar
  28. 28.
    Frankel EN, Waterhouse AL, Kinsella JE (1993) Inhibition of human LDL oxidation by resveratrol. Lancet 341:1103–1104PubMedGoogle Scholar
  29. 29.
    Miller NJ, Rice-Evans CA (1995) Antioxidant activity of resveratrol in red wine. Clin Chem 41:1789PubMedGoogle Scholar
  30. 30.
    Hebbar V, Shen G, Hu R, Kim BR, Chen C, Korytko PJ, Crowell JA, Levine BS, Kong AN (2005) Toxicogenomics of resveratrol in rat liver. Life Sci 76:2299–2314PubMedGoogle Scholar
  31. 31.
    Dore S (2002) Decreased activity of the antioxidant heme oxygenase enzyme: implications in ischemia and in Alzheimer’s disease. Free Radic Biol Med 32:1276–1282PubMedGoogle Scholar
  32. 32.
    Kim YA, Kim GY, Park KY, Choi YH (2007) Resveratrol inhibits nitric oxide and prostaglandin E2 production by lipopolysaccharide-activated C6 microglia. J Med Food 10:218–224PubMedGoogle Scholar
  33. 33.
    Zhuang H, Kim YS, Koehler RC, Dore S (2003) Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann N Y Acad Sci 993:276–286 discussion 287–278PubMedGoogle Scholar
  34. 34.
    Juan SH, Cheng TH, Lin HC, Chu YL, Lee WS (2005) Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. Biochem Pharmacol 69:41–48PubMedGoogle Scholar
  35. 35.
    Olas B, Wachowicz B, Szewczuk J, Saluk-Juszczak J, Kaca W (2001) The effect of resveratrol on the platelet secretory process induced by endotoxin and thrombin. Microbios 105:7–13PubMedGoogle Scholar
  36. 36.
    Orsini F, Pelizzoni F, Verotta L, Aburjai T, Rogers CB (1997) Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-beta-D-glucopyranoside and related compounds. J Nat Prod 60:1082–1087PubMedGoogle Scholar
  37. 37.
    Soleas GJ, Diamandis EP, Goldberg DM (1997) Resveratrol: a molecule whose time has come? and gone? Clin Biochem 30:91–113PubMedGoogle Scholar
  38. 38.
    Shen MY, Hsiao G, Liu CL, Fong TH, Lin KH, Chou DS, Sheu JR (2007) Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol 139:475–485PubMedGoogle Scholar
  39. 39.
    Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220PubMedGoogle Scholar
  40. 40.
    van Ginkel PR, Sareen D, Subramanian L, Walker Q, Darjatmoko SR, Lindstrom MJ, Kulkarni A, Albert DM, Polans AS (2007) Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res 13:5162–5169PubMedGoogle Scholar
  41. 41.
    Trincheri NF, Nicotra G, Follo C, Castino R, Isidoro C (2007) Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis 28:922–931PubMedGoogle Scholar
  42. 42.
    Su JL, Yang CY, Zhao M, Kuo ML, Yen ML (2007) Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol. J Biol Chem 282:19385–19398PubMedGoogle Scholar
  43. 43.
    Harper CE, Patel BB, Wang J, Arabshahi A, Eltoum IA, Lamartiniere CA (2007) Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 28:1946–1953PubMedGoogle Scholar
  44. 44.
    Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB (2007) Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 109:2293–2302PubMedGoogle Scholar
  45. 45.
    Abd El-Mohsen M, Bayele H, Kuhnle G, Gibson G, Debnam E, Kaila Srai S, Rice-Evans C, Spencer JP (2006) Distribution of [3H] trans-resveratrol in rat tissues following oral administration. Br J Nutr 96:62–70PubMedGoogle Scholar
  46. 46.
    Sun C, Hu Y, Liu X, Wu T, Wang Y, He W, Wei W (2006) Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet 165:9–19PubMedGoogle Scholar
  47. 47.
    Busquets S, Ametller E, Fuster G, Olivan M, Raab V, Argiles JM, Lopez-Soriano FJ (2007) Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett 245:144–148PubMedGoogle Scholar
  48. 48.
    Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon EA (2007) Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 28:282–293PubMedGoogle Scholar
  49. 49.
    Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ (2007) Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann N Y Acad Sci 1095:441–448PubMedGoogle Scholar
  50. 50.
    Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, Kim AL (2007) Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224:274–283PubMedGoogle Scholar
  51. 51.
    Cecchinato V, Chiaramonte R, Nizzardo M, Cristofaro B, Basile A, Sherbet GV, Comi P (2007) Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol 74:1568–1574PubMedGoogle Scholar
  52. 52.
    Kundu JK, Shin YK, Kim SH, Surh YJ (2006) Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 27:1465–1474PubMedGoogle Scholar
  53. 53.
    Candelario-Jalil E, de Oliveira AC, Graf S, Bhatia HS, Hull M, Munoz E, Fiebich BL (2007) Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflammation 4:25PubMedGoogle Scholar
  54. 54.
    Kim YA, Kim GY, Park KY, Choi YH (2007) Resveratrol inhibits nitric oxide and prostaglandin E2 production by lipopolysaccharide-activated C6 microglia. J Med Food 10:218–224PubMedGoogle Scholar
  55. 55.
    Sharma S, Chopra K, Kulkarni SK, Agrewala JN (2007) Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin Exp Immunol 147:155–163PubMedGoogle Scholar
  56. 56.
    Singh NP, Hegde VL, Hofseth LJ, Nagarkatti M, Nagarkatti P (2007) Resveratrol (trans-3, 5, 4′-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 72:1508–1521PubMedGoogle Scholar
  57. 57.
    Bertelli A, Falchi M, Dib B, Pini E, Mukherjee S, Das DK (2008) Analgesic resveratrol? Antioxid Redox Signal 10:403–404PubMedGoogle Scholar
  58. 58.
    Parker JA, Arango M, Abderrahmane S, Lambert E, Tourette C, Catoire H, Neri C (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37:349–350PubMedGoogle Scholar
  59. 59.
    Marambaud P, Zhao H, Davies P (2005) Resveratrol promotes clearance of Alzheimer’s disease amyloid-beta peptides. J Biol Chem 280:37377–37382PubMedGoogle Scholar
  60. 60.
    Karlsson J, Emgard M, Brundin P, Burkitt MJ (2000) Trans-resveratrol protects embryonic mesencephalic cells from tert-butyl hydroperoxide: electron paramagnetic resonance spin trapping evidence for a radical scavenging mechanism. J Neurochem 75:141–150PubMedGoogle Scholar
  61. 61.
    Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444:337–342PubMedGoogle Scholar
  62. 62.
    Miyazaki R, Ichiki T, Hashimoto T, Inanaga K, Imayama I, Sadoshima J, Sunagawa K (2008) SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 28:1263–1269PubMedGoogle Scholar
  63. 63.
    Borra MT, Smith BC, Denu JM (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280:17187–17195PubMedGoogle Scholar
  64. 64.
    Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, Napper A, Curtis R, DiStefano PS, Fields S, Bedalov A, Kennedy BK (2005) Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 280:17038–17045PubMedGoogle Scholar
  65. 65.
    Jiang WJ (2008) Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun 373:341–344PubMedGoogle Scholar
  66. 66.
    Guarente L (2007) Sirtuins in aging and disease. Cold Spring Harb Symp Quant Biol 72:483–488PubMedGoogle Scholar
  67. 67.
    Howitz KT et al (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425:191–196PubMedGoogle Scholar
  68. 68.
    Griswold AJ, Chang KT, Runko AP, Knight MA, Min KT (2008) Sir2 mediates apoptosis through JNK-dependent pathways in Drosophila. Proc Natl Acad Sci USA 105:8673–8678PubMedGoogle Scholar
  69. 69.
    Gruber J, Tang SY, Halliwell B (2007) Evidence for a trade-off between survival and fitness caused by resveratrol treatment of Caenorhabditis elegans. Ann N Y Acad Sci 1100:530–542PubMedGoogle Scholar
  70. 70.
    Terzibasi E, Valenzano DR, Cellerino A (2007) The short-lived fish Nothobranchius furzeri as a new model system for aging studies. Exp Gerontol 42:81–89PubMedGoogle Scholar
  71. 71.
    Nisoli E, Tonello C, Cardile A, Cozzi V, Bracale R, Tedesco L, Falcone S, Valerio A, Cantoni O, Clementi E, Moncada S, Carruba MO (2005) Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 310:314–317PubMedGoogle Scholar
  72. 72.
    Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127:1109–1122PubMedGoogle Scholar
  73. 73.
    Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712–716PubMedGoogle Scholar
  74. 74.
    Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, De Oliveira RM, Leid M, McBurney MW, Guarente L (2004) Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-g. Nature 429:771–776PubMedGoogle Scholar
  75. 75.
    Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, Mayo MW (2004) Modulation of NF-kB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369–2380PubMedGoogle Scholar
  76. 76.
    Zhang J (2006) Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem J 397:519–527PubMedGoogle Scholar
  77. 77.
    Blüher M, Kahn BB, Kahn CR (2003) Extended longevity in mice lacking the insulin receptor in adipose tissue. Science 24:572–574Google Scholar
  78. 78.
    Kaestner KH, Knochel W, Martinez DE (2000) Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 14:142–146PubMedGoogle Scholar
  79. 79.
    Greer EL, Brunet A (2005) FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24:7410–7425PubMedGoogle Scholar
  80. 80.
    Accili D, Arden KC (2004) FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. Cell 117:421–426PubMedGoogle Scholar
  81. 81.
    Barthel A, Schmoll D, Unterman TG (2005) FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab 16:183–189PubMedGoogle Scholar
  82. 82.
    Coffer P (2003) OutFOXing the grim reaper: novel mechanisms regulating longevity by forkhead transcription factors. Sci STKE 2003, PE39Google Scholar
  83. 83.
    Morris BJ (2005) A forkhead in the road to longevity: the molecular basis of lifespan becomes clearer. J Hypertens 23:1285–1309PubMedGoogle Scholar
  84. 84.
    Huang H, Tindall DJ (2006) FOXO factors: a matter of life and death. Future Oncol 2:83–89PubMedGoogle Scholar
  85. 85.
    Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857–868PubMedGoogle Scholar
  86. 86.
    Lin K, Dorman JB, Rodan A, Kenyon C (1997) daf-16: An HNF-3/forkhead family member that can function to double the life-span of Caenorhabditis elegans. Science 278:1319–1322PubMedGoogle Scholar
  87. 87.
    Ogg S, Paradis S, Gottlieb S, Patterson GI, Lee L, Tissenbaum HA, Ruvkun G (1997) The Fork head transcription factor DAF-16 transduces insulin-like metabolic and longevity signals in C. elegans. Nature 389:994–999PubMedGoogle Scholar
  88. 88.
    Johnson TE (1990) Increased life-span of age-1 mutants in Caenorhabditis elegans and lower Gompertz rate of aging. Science 249:908–912PubMedGoogle Scholar
  89. 89.
    Kenyon C, Chang J, Gensch E, Rudner A, Tabtiang R (1993) A C. elegans mutant that lives twice as long as wild type. Nature 366:461–464PubMedGoogle Scholar
  90. 90.
    Morris JZ, Tissenbaum HA, Ruvkun G (1996) A phosphatidylinositol-3-OH kinase family member regulating longevity and diapause in Caenorhabditis elegans. Nature 382:536–539PubMedGoogle Scholar
  91. 91.
    Kimura KD, Tissenbaum HA, Liu Y, Ruvkun G (1997) daf-2, an insulin receptor-like gene that regulates longevity and diapause in Caenorhabditis elegans. Science 277:942–946PubMedGoogle Scholar
  92. 92.
    Biggs WH, Meisenhelder J, Hunter T, Cavenee WK, Arden KC (1999) Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1. Proc Natl Acad Sci USA 96:7421–7426PubMedGoogle Scholar
  93. 93.
    Takaishi H, Konishi H, Matsuzaki H, Ono Y, Shirai Y, Saito N, Kitamura T, Ogawa W, Kasuga M, Kikkawa U, Nishizuka Y (1999) Regulation of nuclear translocation of forkhead transcription factor AFX by protein kinase B. Proc Natl Acad Sci USA 96:11836–11841PubMedGoogle Scholar
  94. 94.
    Brunet A, Kanai F, Stehn J, Xu J, Sarbassova D, Frangioni JV, Dalal SN, DeCaprio JA, Greenberg ME, Yaffe MB (2002) 14–3-3 transits to the nucleus and participates in dynamic nucleocytoplasmic transport. J Cell Biol 156:817–828PubMedGoogle Scholar
  95. 95.
    Dougherty MK, Morrison DK (2004) Unlocking the code of 14–3-3. J Cell Sci 117:1875–1884PubMedGoogle Scholar
  96. 96.
    Dudley JI, Lekli I, Mukherjee S, Das M, Bertelli AA, Das DK (2008) Does white wine qualify for French paradox? Comparison of the cardioprotective effects of red and white wines and their constituents: resveratrol, tyrosol, and hydroxytyrosol. J Agric Food Chem 56:9362–9373PubMedGoogle Scholar
  97. 97.
    Kirkwood TB, Austad SN (2000) Why do we age? Nature 408:233–238PubMedGoogle Scholar
  98. 98.
    Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, Burgering BM (2004) FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 23:4802–4812PubMedGoogle Scholar
  99. 99.
    Oh SW, Mukhopadhyay A, Svrzikapa N, Jiang F, Davis RJ, Tissenbaum HA (2005) JNK regulates lifespan in Caenorhabditis elegans by modulating nuclear translocation of forkhead transcription factor/DAF-16. Proc Natl Acad Sci USA 102:4494–4499PubMedGoogle Scholar
  100. 100.
    Wang MC, Bohmann D, Jasper H (2005) JNK extends life span and limits growth by antagonizing cellular and organism-wide responses to insulin signaling. Cell 121:115–125PubMedGoogle Scholar
  101. 101.
    Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I (2004) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426–430PubMedGoogle Scholar
  102. 102.
    Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91(1):295–299PubMedGoogle Scholar
  103. 103.
    Luk T, Malam Z, Marshall JC (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83(4):804–816PubMedGoogle Scholar
  104. 104.
    Silva RM, Duarte IC, Paredes JA, Lima-Costa T, Perrot M, Boucherie H, Goodfellow BJ, Gomes AC, Mateus DD, Moura GR, Santos MA (2009) The yeast PNC1 longevity gene is up-regulated by mRNA mistranslation. PLoS One 4(4):e5212PubMedGoogle Scholar
  105. 105.
    Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C (2006) Structure of Nampt/PBEF/visfatin, a mammalian NAD + biosynthetic enzyme. Nat Struct Mol Biol 13(7):661–662PubMedGoogle Scholar
  106. 106.
    Marshall JC, Malam Z, Jia S (2007) Modulating neutrophil apoptosis. Novartis Found Symp 280:53–66 discussion 67–72, 160–164PubMedGoogle Scholar
  107. 107.
    Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, Wang Y, Raederstorff D, Morrow JD, Leeuwenburgh C, Allison DB, Saupe KW, Cartee GD, Weindruch R, Prolla TA (2008) A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 3(6):e2264PubMedGoogle Scholar
  108. 108.
    Moskovitz J, Bar-Noy S, Williams WM, Requena J, Berlett BS, Stadtman ER (2001) Methionine sulfoxide reductase (MsrA) is a regulator of antioxidant defense and lifespan in mammals. Proc Natl Acad Sci USA 98(23):12920–12925PubMedGoogle Scholar
  109. 109.
    Ruan H, Tang XD, Chen ML, Joiner ML, Sun G, Brot N, Weissbach H, Heinemann SH, Iverson L, Wu CF, Hoshi T (2002) High-quality life extension by the enzyme peptide methionine sulfoxide reductase. Proc Natl Acad Sci USA 99:2748–2753PubMedGoogle Scholar
  110. 110.
    Grubisha O, Smith BC, Denu JM (2005) Small molecule regulation of Sir2 protein deacetylases. FEBS J. 272:4607–4616PubMedGoogle Scholar
  111. 111.
    Anderson RM, Bitterman KJ, Wood JG, Medvedik O, Sinclair DA (2003) Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature 423(6936):181–185PubMedGoogle Scholar
  112. 112.
    Revollo JR, Grimm AA, Imai S (2004) The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 279:50754–50763PubMedGoogle Scholar
  113. 113.
    Streppel MT, Ocke MC, Boshulzen HC, Kok FJ, Kromhout D (2009) Long-term wine consumption is related to cardiovascular mortality and life expectancy independently of moderate alcohol intake: the Zutphen Study. J Epidemiol Community Health 63:534–540PubMedGoogle Scholar
  114. 114.
    Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425(6954):191–196PubMedGoogle Scholar
  115. 115.
    Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R (2008) Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 8:157–168PubMedGoogle Scholar
  116. 116.
    Pacholec M, Chrunyk B, Cunningham D, Flynn D, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K (2010) SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 285:8340–8351Google Scholar
  117. 117.
    Cumine S, Kim KW, Lu S-C, Atangan L, Wang M (2009) Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Design 74:619–624Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Dipak K. Das
    • 1
    Email author
  • Subhendu Mukherjee
    • 1
  • Diptarka Ray
    • 1
  1. 1.Cardiovacular Research CenterUniversity of Connecticut School of MedicineFarmingtonUSA

Personalised recommendations